Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for Treatment-Naive CLL Ulas D. Bayraktar, MD 2025-03-14
Mantle cell lymphoma New Indication: Ibrutinib with Venetoclax for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-03-02
Chronic Lymphocytic Leukemia New Protocol: Acalabrutinib + Venetoclax for Fixed Duration with/without Obinutuzumab Ulas D. Bayraktar, MD 2025-02-07
Mantle cell lymphoma New Protocol: Acalabrutinib with R-Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-01-19
Diffuse Large B Cell Lymphoma New Drug: Glofitamab for Large B Cell Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
Follicular Lymphoma New Indication: Zanubrutinib and Obinutuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-09-23
Diffuse Large B Cell Lymphoma New Drug: Glofitamab in Large B-Cell Lymphoma Ulas D. Bayraktar, MD 2023-08-20
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
